Merck, Inc.
🇵🇭Philippines
5 Year Long-term Follow up in Pediatric Participants Who Received PegIntron Plus Rebetol in P02538 Part I (P02538 Pt 2)
Phase 3
Completed
- Conditions
- Hepatitis C, Chronic
- Interventions
- Biological: Peginterferon alfa-2bDrug: Ribavirin
- First Posted Date
- 2008-09-29
- Last Posted Date
- 2017-04-04
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 94
- Registration Number
- NCT00761735
Comparing 4.0 mg.Kg-1 Sugammadex With Placebo in the Reversal of Profound Neuromuscular Blockade (P05767)
Phase 3
Completed
- Conditions
- AnesthesiaNeuromuscular Blockade
- Interventions
- Drug: 0.9% sodium chloride (NaCl)Drug: Sugammadex
- First Posted Date
- 2008-09-25
- Last Posted Date
- 2015-08-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 140
- Registration Number
- NCT00758485
A Multiple-Dose Study of MK-1006 (MK-1006-004)(TERMINATED)
Phase 1
Terminated
- Conditions
- Type 2 Diabetes
- Interventions
- Drug: MK-1006
- First Posted Date
- 2008-09-25
- Last Posted Date
- 2016-02-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 112
- Registration Number
- NCT00758680
A Study to Test the Safety and Effectiveness of MK-0974 (Telcagepant) Co-administered With Ibuprofen or Acetaminophen in Patients With Migraines With or Without Aura (MK-0974-046)
Phase 2
Completed
- Conditions
- Migraine
- Interventions
- First Posted Date
- 2008-09-25
- Last Posted Date
- 2018-10-22
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 683
- Registration Number
- NCT00758836
A Study of Dalotuzumab (MK-0646) in Breast Cancer Patients (MK-0646-013)
- First Posted Date
- 2008-09-25
- Last Posted Date
- 2018-08-15
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 48
- Registration Number
- NCT00759785
Pegylated Alfa-2b Interferon Therapy of Patients With Hepatitis C-related Cirrhosis and High Liver Cell Proliferation (P02733/MK-4031-085)
Phase 3
Completed
- Conditions
- Carcinoma, Hepatocellular
- Interventions
- Biological: Peginterferon alfa-2bOther: Observation (no treatment)
- First Posted Date
- 2008-09-25
- Last Posted Date
- 2017-04-07
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 150
- Registration Number
- NCT00759109
Clinical Study on Sitagliptin for Assessment of Glucose-lowering Effects (0431-045)
Phase 2
Completed
- Conditions
- Diabetes Mellitus, Non-Insulin-Dependent
- Interventions
- First Posted Date
- 2008-09-23
- Last Posted Date
- 2017-05-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 80
- Registration Number
- NCT00758069
A Study to Assess Regional Cerebral Blood Flow as an Alzheimer's Disease Biomarker Compared to Positron Emission Tomography in Patients With Mild-to-Moderate Alzheimer's Disease and Cognitively Normal Elderly Subjects (Study MK-0000-068)(COMPLETED)
Phase 1
Completed
- Conditions
- Alzheimer's Disease
- Interventions
- Other: MRIOther: FDG-PET
- First Posted Date
- 2008-09-23
- Last Posted Date
- 2015-08-11
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 40
- Registration Number
- NCT00757939
A Study to Test the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK1006 (MK-1006-002)(COMPLETED)
Phase 1
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: MK1006Drug: Placebo
- First Posted Date
- 2008-09-23
- Last Posted Date
- 2016-02-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 25
- Registration Number
- NCT00757601
Remicade® Crohn's Disease Registry Across Canada (Study P02793)
Terminated
- Conditions
- Crohn's Disease
- Interventions
- Other: Data collection post infusion
- First Posted Date
- 2008-09-19
- Last Posted Date
- 2015-06-22
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 556
- Registration Number
- NCT00755937
© Copyright 2025. All Rights Reserved by MedPath